paroxetine has been researched along with Elevated Cholesterol in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hu, MY; Jia, LL; Li, F; Liu, C; Liu, L; Liu, XD; Xu, D; Yang, Y; Zhang, M; Zhong, ZY | 1 |
Baker, R; Jackson, D | 1 |
Gutierrez, AM; Mohammadi, M; Weber, M | 1 |
Archer, SL; Baker, GB; Lara, N; Le Mellédo, JM | 1 |
4 other study(ies) available for paroxetine and Elevated Cholesterol
Article | Year |
---|---|
Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.
Topics: Animals; Anticholesteremic Agents; Antidepressive Agents, Second-Generation; Blood Glucose; Cell Line; Depression; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Drug Interactions; Hypercholesterolemia; Insulin; Male; Paroxetine; Pravastatin; Rats; Rats, Sprague-Dawley; Serotonin | 2014 |
New models for describing outliers in meta-analysis.
Topics: Algorithms; Cognition Disorders; Cytidine Diphosphate Choline; Dental Caries; Fluorides; Humans; Hypercholesterolemia; Meta-Analysis as Topic; Models, Statistical; Monte Carlo Method; Paroxetine; Placebos; Pravastatin; Regression Analysis; Research Design; Software; Statistics as Topic; Toothpastes | 2016 |
The risks and benefits of switching antipsychotics: a case study approach.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertriglyceridemia; Long-Term Care; Male; Middle Aged; Olanzapine; Paroxetine; Psychotic Disorders; Risk Assessment; Schizophrenia; Thioridazine | 2009 |
Increased cholesterol levels during paroxetine administration in healthy men.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Male; Paroxetine; Reference Values; Risk; Selective Serotonin Reuptake Inhibitors; Triglycerides | 2003 |